At the Annual European Congress on Rheumatology (EULAR 2016), held last week in London, Samsung Bioepis presented new clinical data on its etanercept, adalimumab, and infliximab biosimilars.  According to a press release from Biogen, a partner in the Samsung Bioepis joint venture with Samsung BioLogics, Phase III studies for those anti-TNF-α biosimilars have demonstrated that switching from the reference product to Samsung Bioepis’s biosimilar results in comparable efficacy and safety profiles in patients.  As we recently reported, Samsung Bioepis’s infliximab biosimilar is currently under FDA review and has already received marketing authorization in the EU.